Soluble CD40 ligand is elevated in Type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function

Platelets

Volumn 21, Issue 7, 2010, Pages 525-532

  Lajer, Maria ^a   Tarnow, Inge ^b   Michelson, Alan D ^c   Jorsal, Anders ^a   Frelinger, Andrew L ^c   Parving, Hans Henrik ^d,e   Rossing, Peter ^a   Tarnow, Lise ^a  

^a STENO DIABETES CENTER   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d Rigshospitalet   (Denmark)

^e AARHUS UNIVERSITY   (Denmark)

Author keywords

Cardiovascular disease; cd40l; diabetic nephropathy; type 1 diabetes

Indexed keywords

CD40 LIGAND; SOLUBLE CD40 LIGAND; UNCLASSIFIED DRUG;

ADULT; ALBUMINURIA; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE DURATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL;

ADULT; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CD40 LIGAND; DENMARK; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 77957986157     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2010.500422     Document Type: Article

References (35)

1. Parving H-H, Mauer M, Ritz E. Brenner and Rector's The Kidney. In: Brenner BM, editor. Diabetic Nephropathy. 7th edn. Boston, USA: WB Saunders; 2004. pp 1777-1818.
2. Rossing P, Hougaard P, Borch-Johnsen K. Parving H-H. Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. BMJ 1996;7060:779-784.
3. Henn V, Slupsky JR, Gräfe M, Anagnostopoulos I, Fürster R, Müller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;6667:591-594.
4. André P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Platelet-derived CD40L: The switch-hitting player of cardiovascular disease. Circulation 2002;8:896-899.
5. Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001;1:4-43.
6. Tanaka T, Kuroiwa T, Ikeuchi H, Ota F, Kaneko Y, Ueki K, Tsukada Y, McInnes IB, Boumpas DT, Nojima Y. Human platelets stimulate mesangial cells to produce monocyte chemoattractant protein-1 via the CD40/CD40 ligand pathway and may amplify glomerular injury. JASN 2002; 10:2488-2496.
7. Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998;6689:200-203.
8. Schonbeck U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD40L and cardiovascular risk in women. Circulation 2001;19:2266-2268.
9. Aukrust P, Müller F, Ueland T, Berget T, Aaser E, Brunsvig A, Solum NO, Forfang K, Fröland SS, Gullestad L. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999;6:614-620.
10. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, Simoons ML. CAPTURE Study I. Soluble CD40 ligand in acute coronary syndromes. New Engl J Med 2003;12:1104-1111.
11. Olenchock BA, Wiviott SD, Murphy SA, Cannon CP, Rifai N, Braunwald E, Morrow DA. Lack of association between soluble CD40L and risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16. J Thromb Thrombol 2008;2:79-84.
12. Lim HS, Blann AD, Lip GY. Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: Relationships to cardiovascular disease and risk factor intervention. Circulation 2004;21:2524-2528.
13. Varo N, Vicent D, Libby P, Nuzzo R, Calle-Pascual AL, Bernal MR, Fernbndez-Cruz A, Veves A, Jarolim P, Varo JJ, et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation 2003;21:2664-2669.
14. Yngen M, Ostenson CG, Hu H, Li N, Hjemdahl P, Wallen NH. Enhanced P-selectin expression and increased soluble CD40 Ligand in patients with Type 1 diabetes mellitus and microangiopathy: Evidence for platelet hyperactivity and chronic inflammation. Diabetologia 2004;3:537-540.
15. Tarnow I, Michelson AD, Barnard MR, Frelinger AL III, Aasted B, Jensen BR, Parving HH, Rossing P, Tarnow L. Nephropathy in type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity. Platelets 2009;7:513-519.
16. Tarnow L, Groop PH, Hadjadj S, Kazeem G, Cambien F, Marre M, Forsblom C, Parving HH, Trqgoudt D, Thqvard A, et al. *EURAGEDIC Consortium. European rational approach for the genetics of diabetic complica-tions-EURAGEDIC: Patient populations and strategy. Nephrol Dial Transpl 2008;1:161-168.
17. Bröchner-Mortensen J, Rödbro P. Selection of routine method for determination of glomerular filtration rate in adult patients. Scand J Clin Lab Invest 1976;:35-45.
18. Furman MI, Krueger LA, Linden MD, Barnard MR, Frelinger AL III, Michelson AD. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J Am Col Cardiol 2004;12:2319-2325.
19. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray J, Michelson EL, Olofsson B, Ostergren J, Yusuf S. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. The Lancet 2003;9386:759-766.
20. Keaney Jr JF, Lipinska I, Larson MG, Dupuis J, Freedman JE, Hamburg NM, Massaro JM, Rong J, Sutherland P, Vita JA, et al. Clinical correlates, heritability, and genetic linkage of circulating CD40 ligand in the Framingham Offspring Study. Am Heart J 2008;5:1003-1009.
21. Astrup AS, Tarnow L, Pietraszek L, Schalkwijk CG, Stehouwer CDA, Parving HH, Rossing P. Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: Association with mortality and decline of glomerular filtration rate. Diabetes Care 2008;6:1170-1176.
22. Mauer SM, Steffes MW, Ellis EN, Sutherland DER, Brown DM, Goetz FC. Structural-functional relationships in diabetic nephropathy. J Clin Invest 1984;:1143-1155.
23. Kairaitis L, Wang Y, Zheng L, Tay YC, Wang Y, Harris DC. Blockade of CD40-CD40 ligand protects against renal injury in chronic proteinuric renal disease. Kidney Int 2003;4:1265-1272.
24. Ferroni P, Guagnano MT, Falco A, Paoletti V, Manigrasso MR, Michetti N, Santilli F, Guadagni F, Basili S, Davi G. Association of low-grade inflammation and platelet activation in patients with hypertension with microalbuminuria. Clin Sci 2008;6:449-455.
25. Hovind P. Initiation, progression and remission of diabetic nephropathy. Dan Med Bull 2005;4:119-142.
26. Chiarelli F, Giannini C, Verrotti A, Mezzetti A, Mohn A. Increased concentrations of soluble CD40 ligand may help to identify type 1 diabetic adolescents and young adults at risk for developing persistent microalbuminuria. Diabetes-Metab Res 2008;7:570-576.
27. Assert R, Scherk G, Bumbure A, Pirags V, Schatz H, Pfeiffer AF. Regulation of protein kinase C by short term hypergly-caemia in human platelets in vivo and in vitro. Diabetologia 2001;2:188-195.
28. Rabini RA, Staffolani R, Fumelli P, Mutus B, Curatola G, Mazzanti L. Decreased nitric oxide synthase activity in platelets from IDDM and NIDDM patients. Diabetologia 1998;1:101-104.
29. Schrijvers BF, Vriese De, Flyvbjerg AS, A. From hypergly-cemia to diabetic kidney disease: The role of metabolic, hemodynamic, intracellular factors and growth factors/cyto-kines. Endocrine Rev 2004;6:971-1010.
30. Andre P, Prasad KS, Denis CV, He M, Papalia JM, Hynes RO, Phillips DR, Wagner DD. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nature Med 2002;3:247-252.
31. Pajukanta P, Cargill M, Viitanen L, Nuotio I, Kareinen A, Perola M, Terwilliger JD, Kempas E, Daly M, Lilja H, et al. Two loci on chromosomes 2 and X for premature coronary heart disease identified in early-and late-settlement populations of Finland. Am J Human Gene 2000;6:1481-1493.
32. Bowden DW, Sale M, Howard TD, Qadri A, Spray BJ, Rothschild CB, Akots G, Rich SS, Freedman BI. Linkage of genetic markers on human chromosomes 20 and 12 to NIDDM in Caucasian sib pairs with a history of diabetic nephropathy. Diabetes 1997;5:882-886.
33. Ji L, Malecki M, Warram JH, Yang Y, Rich SS, Krolewski AS. New susceptibility locus for NIDDM is localized to human chromosome 20q. Diabetes 1997;5:876-881.
34. Burdon KP, Langefeld CD, Beck SR, Wagenknecht LE, Carr JJ, Rich SS, Freedman BI, Herrington D, Bowden DW. Variants of the CD40 gene but not of the CD40L gene are associated with coronary artery calcification in the Diabetes Heart Study (DHS). Am Heart J 2006;3:706-711.
35. Mason PJ, Chakrabarti S, Albers AA, Rex S, Vitseva O, Varghese S, Freedman JE. Plasma, serum, and platelet expression of CD40 ligand in adults with cardiovascular disease. Am J Cardiol 2005;10:1365-1369.